The CD112R/CD112 axis: a breakthrough in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• Immune checkpoint inhibitors (ICIs) are a breakthrough in cancer treatment, but drug resistance limits efficacy.
• CD112R (PVRIG) is an emerging co-inhibitory receptor on NK and T cells that suppresses anti-cancer immune responses.
• CD112, its ligand, is found on antigen-presenting and tumor cells and associated with poor prognosis.

Purpose of the Study:

• To review the molecular and functional interactions of CD112R with other immune checkpoints like TIGIT, CD96, and CD226.
• To discuss the therapeutic potential of targeting the CD112R/CD112 axis in cancer immunotherapy.
• To explore the role of CD112R/CD112 in cancer prognosis.

Main Methods:

• Literature review of preclinical and clinical studies.
• Analysis of molecular interactions between CD112R, CD112, and other immune checkpoints.
• Discussion of therapeutic strategies targeting the CD112R/CD112 pathway.

Main Results:

• CD112R binding to CD112 inhibits T cell and NK cell responses against cancer.
• The CD112R/CD112 pathway represents a novel immune checkpoint with potential therapeutic applications.
• Understanding CD112R's role may help predict patient response and improve cancer immunotherapy outcomes.

Conclusions:

• CD112R/CD112 is a significant target for overcoming resistance in cancer immunotherapy.
• Further research into CD112R-based therapies could enhance treatment efficacy and patient prognosis.
• This pathway offers a new avenue for developing next-generation immunotherapies.